Table 2.
Model input data.
| Model input | Base-case value | Distribution | Source |
|---|---|---|---|
| Assumed WTP per QALY | $63.593 | - | McDougal (15) |
| Starting age | 66 years | - | Assumption |
| Discount rate | 3.00% | - | Assumption |
| Costs | |||
| Stroke hospitalization costs (mRS 0–2/3–5/6) | $26,705/$106,533/$88,159 | γ | Mu (16) |
| Costs of first 90 days after discharge (mRS 0–2/3–5) | $15,213/$26,496 | γ | |
| Total costs day 91–365 after stroke (mRS 0–2 and 3–5) | $24,988/$35,140 | γ | |
| Additional cost EVT | $17,103 | γ | Shireman (12) |
| Additional cost stent implantation | $9,000 | γ | Stryker, United States |
| Acute care costs recurrent stroke | $29,259 | γ | Chambers (17) |
| Long-term annual cost after stroke for mRS 0/1/2/3/4/5 | $14,230/$14,653/$16,952/$29,107/$58,913/$86,612 | γ | Shireman (12) |
| Initial probabilities | |||
| Underlying basilar stenosis in acute basilar artery occlusion | 0.397 ± 0.107 | - | Summarized results of ATTENTION, BAOCHE, BASICS, BEST (3, 5–7) |
| Functional outcome 90d after EVT mRS 0/1/2/3/4/5/6 | 6.5/16.5/14.0/9.5/7.0/12.75/33.75 | - | |
| Functional outcome 90 days after BMC mRS 0/1/2/3/4/5/6 | 3.75/7.0/8.0/9.25/13.75/12.5/45.75 | - | |
| Acute stenting of observed basilar stenosis in initial EVT | 0.618 | - | |
| Transition probabilities | |||
| Stroke recurrence (year 1–10) | 0.059/0.036/0.025/0.022 / 0.022 / 0.027 / 0.027 / 0.023 / 0.028 / 0.016 | - | Pennlert (18) |
| Annual death hazard ratios for survivors mRS 0/1/2/3/4/5 | 0.129/0.136/0.164/0.247/0.135/0.189 | - | Hong (19) |
| Outcome after recurrent stroke in mRS 0 or 1/2/3/4/5/6 | 0.129/0.136/0.164/0.247/0.135/0.189 | - | Goyal (20) |
| Age-adjusted mortality | U.S. life tables | - | Arias (21) |
| RR for stroke recurrence with underlying basilar stenosis | 3.4 | - | Gulli (14) |
| HR for in-stent thrombosis | 1.057 | - | Riedel (22) |
| Utilities | |||
| Quality of life (mRS Score 0–5) | 1.00/0.91/0.76/0.65/0.33/0.00/0.00 | β | Chaisinanukul (23) |